Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-131X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib ; volume:28 ; number:4 ; day:10 ; month:8 ; year:2010 ; pages:1527-1529 ; date:12.2011
Medical oncology ; 28, Heft 4 (10.8.2010), 1527-1529, 12.2011
- Urheber
-
Molina, Ana M.
Ginsberg, Michelle S.
Motzer, Robert J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12032-010-9640-y
- URN
-
urn:nbn:de:101:1-2021082820474263148952
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Molina, Ana M.
- Ginsberg, Michelle S.
- Motzer, Robert J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report